沙库巴曲缬沙坦联合螺内酯治疗老年慢性心力衰竭的临床效果及其对患者心室重塑的短期影响

目的探讨沙库巴曲缬沙坦联合螺内酯治疗老年慢性心力衰竭的临床效果及其对患者心室重塑的短期影响。方法选取2018年2月至2019年2月阜阳市第二人民医院收治的86例老年慢性心力衰竭患者为研究对象,采用随机数字表法将入选患者分为观察组和对照组,每组各43例。在常规治疗基础上,分别给予对照组和观察组患者缬沙坦联合螺内酯、沙库巴曲缬沙坦联合螺内酯治疗,两组患者均治疗3个月。比较两组患者治疗前后左室射血分数(left ventricular ejection fraction,LVEF)、左室收缩末期容积(left ventricular end systolic volume,LVESV)、左室舒张末期容积(left ventricular end diastolic volume,LVEDV)、室间隔厚度(interventricular septum thickness,IVST)、血清N末端B型利钠肽原(N-terminal pro-Btype natriuretic peptide,NT-proBNP)、转化生长因子-β(transforming growth factor-β,TGF-β)、基质金属蛋白酶-9(matrix metalloproteinase-9,MMP-9)、基质金属蛋白酶抑制剂-1(tissue inhibitors of metalloproteinases-1,TIMP-1)水平、临床疗效和安全性。结果两组患者治疗后3个月LVEF和TIMP-1水平均显著高于本组治疗前(均P<0.05),LVESV、LVEDV、IVST、血清NT-proBNP、TGF-β、MMP-9水平均显著低于本组治疗前(均P<0.05)。观察组患者治疗后3个月LVEF、TIMP-1水平均显著高于对照组(P<0.05),LVESV、LVEDV、IVST、血清NT-proBNP、TGF-β、MMP-9水平均显著低于对照组(均P<0.05)。观察组患者治疗总有效率显著高于对照组(P<0.05)。两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论沙库巴曲缬沙坦联合螺内酯能显著改善老年慢性心力衰竭患者的心室重塑,临床疗效优于缬沙坦联合螺内酯,安全可靠。

泛福舒在儿童过敏性鼻炎并发上气道咳嗽综合征的应用

目的 探讨泛福舒在治疗儿童过敏性鼻炎并发上气道咳嗽综合征中的临床疗效及免疫调节作用.方法 选取云浮市人民医院2022年6月-2023年6月收治的60例儿童过敏性鼻炎患者作为研究对象,采用随机对照法均分为试验组及对照组,每组各30例.对照组采用常规治疗,试验组给予常规治疗联合泛福舒治疗,分别收集试验组及对照组治疗前以及治疗后的鼻部症状评分、咳嗽症状积分(包括日间积分和夜间积分)、血清总IgE及吸入性过敏原过筛试验(hx2)和食物过敏原过筛试验(fx5E),比较两组患儿治疗前后鼻部症状评分总分、日间咳嗽症状积分、夜间咳嗽症状积分、血清总IgE及吸入性过敏原过筛试验(hx2)和食物过敏原过筛试验(fx5E)之间的差异.结果 试验组治疗后鼻部症状评分总分、日间咳嗽症状积分、夜间咳嗽症状积分、血清总IgE及吸入性过敏原过筛试验(hx2)下降程度较对照组明显,差异具有统计学意义(P<0.05).结论 泛福舒在儿童过敏性鼻炎并发上气道咳嗽综合征的治疗中可有效缓解咳嗽及鼻部症状,同时可减轻过敏症状及过敏反应,对免疫调节也有积极作用,值得推广并使用.

Suppression of murine breast cancer metastasis by selective inhibition of CXCR4 by synthetic polypeptide derived from viral macrophage inflammatory protein Ⅱ

Stromal cell-derived factor-1 and its receptor CXC chemokine receptor-4(CXCR4)have been implicated in breast cancer metastasis.A significant association between HER2 and CXCR4 expression has been observed in human breast tumor tissues,and overexpression of CXCR4 is essential for HER2-mediated tumor metastasis.Moreover,CXCR4 expression is low in normal breast tissues and high in malignant tumors,suggesting that a blockade of CXCR4 may limit tumor metastasis.The present study investigated the action of a synthetic antagonist 21-mer peptide derived from viral macrophage inflammatory protein Ⅱ against CXCR4(NT21MP)in inhibiting metastasis in vitro and in vivo.The results showed that chemotaxis of SKBR3 cells toward SDF-1αwas reduced by NT21MP in a dose-dependent manner(P<0.05).NT21MP inhibited tumor growth at 500μg/kg and in combination with Herceptin,the anti-HER2 antibody.The in vivo metastatic assay showed that NT21MP significantly inhibited pulmonary metastasis,and the number of metastatic tumor nodes on the surface of the lung was greatly decreased.Compared with the saline-treated control group,PCNA expression was dose-dependently decreased by NT21MP,the percentage of apoptotic cells was increased,and CXCR4 mRNA and protein expression were downregulated.In conclusion,NT21MP inhibits cellular proliferation,promotes apoptosis by downregulating CXCR4 expression,and suppresses the progression of primary and metastatic tumors.CXCR4 may be a useful therapeutic target for breast cancer,and NT21MP may serve as a potential target drug for the treatment of breast cancer metastasis.